ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1127

Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set

Amara Shaukat1, Tim Jansen2, M. Janssen3, Leo .A.B. Joosten4, Timothy Radstake5, Philip Riches6, Anne-Kathrin Tausche7, Jennie Harre Hindmarsh8, Nicola Dalbeth9, Lisa K. Stamp10 and Tony R. Merriman11, 1Univ Otago, Dunedin, New Zealand, 2VieCuri Medical Center, Venlo, Netherlands, 3Rheumatology Dept, Rijnstate Hospital, Arnhem, Netherlands, 4Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 5Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 6University of Edinburgh, Edinburgh, United Kingdom, 7Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, 8Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, 9University of Auckland, Auckland, New Zealand, 10University of Otago, Christchurch, New Zealand, 11Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: genetics, gout, inflammasome activation and polymorphism

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout results from formation of monosodium urate (MSU) crystals in the presence of hyperuricemia. Genome wide association studies have provided significant insights into hyperuricemia, however,the genetic basis of the progression from hyperuricemia to gout is still unclear. Previously, Chang et al (Rheumatology 2016;56:457-466) reported an association of the peroxisome proliferator-activated receptor gamma coactivator 1B (PPARGC1B) missense variant rs45520937 A-allele with gout risk in a Taiwan Han Chinese population (OR= 1.96, POR = 4.0 × 10−10) [1]. PPARGC1B is a regulator of NOD-like receptor family pyrin domain containing 3 inflammasome (NLRP3)-activated inflammation. Our aim was to replicate the rs45520937 association in New Zealand (NZ) Polynesian (Māori and Pacific) and European ancestral groups to investigate the association of PPARGC1B variant with gout.

Methods: A total of 2645 clinically-ascertained gout cases based on American Rheumatism Association 1977 criteria and 2125 controls were utilized from the NZ population. There were 1143 Māori and Pacific (Polynesian) people with gout and 1241 without gout. The European data set was comprised of people with gout from Germany, The Netherlands and Scotland (n=571), and New Zealand (n=931) and 884 people without gout. Taqman® genotyping of PPARGC1B rs45520937 was undertaken, followed by multivariate-adjusted association analysis in R 3.2.2 version with gout as the outcome.

Results: The A-allele was at a lower prevalence in European controls compared to Polynesian controls (0.055 vs 0.418). The A-allele of rs45520937 was associated with increased risk of gout in the Polynesian sample set (OR= 1.17 [1.02-1.35], P=0.02) but not in the European sample set (OR=0.96 [0.73-1.27], P=0.81).

Conclusion: We replicated the association between the PPARGC1B risk A-allele of rs45520937 and gout in the NZ Polynesian group. However this association was not evident in the European group suggesting that this population-specific effect is restricted to the Asia-Pacific region. PPARGC1B is one of several inducible nodes, including PPARg and AMPK-activated protein kinase, in the complex regulatory network for damping NLRP3 inflammasome activation and the inflammatory arthritis phenotype in gout.


Disclosure: A. Shaukat, None; T. Jansen, None; M. Janssen, None; L. A. B. Joosten, None; T. Radstake, None; P. Riches, None; A. K. Tausche, None; J. Harre Hindmarsh, None; N. Dalbeth, Takeda, AstraZeneca, Abbvie, 9; L. K. Stamp, Amgen, 8; T. R. Merriman, Ardea Biosciences, 2.

To cite this abstract in AMA style:

Shaukat A, Jansen T, Janssen M, Joosten LAB, Radstake T, Riches P, Tausche AK, Harre Hindmarsh J, Dalbeth N, Stamp LK, Merriman TR. Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/replication-of-genetic-association-of-peroxisome-proliferator-activated-receptor-gamma-1b-with-gout-in-a-new-zealand-polynesian-sample-set/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/replication-of-genetic-association-of-peroxisome-proliferator-activated-receptor-gamma-1b-with-gout-in-a-new-zealand-polynesian-sample-set/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology